ClinicalTrials.gg
RecruitingNCT05390892PRECIDENTDUpdated Apr 13, 2026

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

A Phase 4 interventional study of SGLT2 inhibitor and GLP-1 receptor agonist in Type2Diabetes and ASCVD, sponsored by Brigham and Women's Hospital. Recruiting at 36 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Brigham and Women's Hospital · Phase 4, Interventional, and Prevention

How we know · 6 judgments

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,000
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 507 studies testing SGLT2 inhibitors in Diabetes Mellitus, Type 2 — 47 open to participants now, 57 under way, 11 of them phase 3. A drug class: SGLT2 inhibitors · Diabetes Mellitus, Type 2.

Planned enrollment
6th of 507
6,000 · median 90
Started
2022
with 22 others
Phase 4
158 of 507
25 open now
Primary completion
2029-03
later than 53 of 56 live
Registered
422nd of 507
by date

Among the 507 studies testing SGLT2 inhibitors in Diabetes Mellitus, Type 2, this one is the 6th largest by planned enrollment, is one of 23 that started in 2022, is one of 158 in phase 4, reaches primary completion later than 53 of the 56 other live ones, and was the 422nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

47 of the 507 studies testing SGLT2 inhibitors in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

42 more — sign in →

By country, each count listing its studies:

All 47 open studies →

About SGLT2 inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 507 studies testing SGLT2 inhibitors in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will be followed for the occurrence of the trial primary endpoint of the total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, counting all events from randomization until end of study.

03

Conditions studied

  • Type2Diabetes
  • ASCVD
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes based on clinical diagnosis
  • ≥6% measured within 12 months prior to screening
  • Secondary prevention cohort (at least 70% of cohort):

    • Age 40 to 80 years
    • Evidence of established atherosclerotic cardiovascular disease (ASCVD), as defined by one or more of the following
    • Coronary heart disease defined by at least one of the following: prior myocardial infarction, prior coronary percutaneous coronary intervention, ≥50% stenosis of a coronary artery documented by invasive or non-invasive imaging (including CT coronary angiography), positive stress test, or coronary artery calcium score >400 Agatston units;
    • Cerebrovascular disease defined by at least one of the following: prior ischemic stroke, prior carotid revascularization procedure, carotid stenosis ≥ 50% documented by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound;
    • Symptomatic peripheral artery disease defined by at least one of the following: leg symptoms with an ABI ≤ 0.9, leg symptoms with imaging evidence of a stenosis ≥50% in a peripheral artery documented by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound, or prior amputation for atherosclerotic disease.
  • Primary prevention cohort (capped at 30% of cohort):

    • Age 60-80 years and at least 1 additional high-risk feature:
    • Cardiovascular risk factors/high-risk features:
    • Active smoking (combustible tobacco or marijuana)
    • HbA1c ≥ 8% measured within 12 months prior to screening. The most recent value available at the time of screening will be used for screening and to determine eligibility.
    • Stage 3a CKD, 45-59 ml/min/1.73m2 measured within 12 months prior to screening. The most recent value available at screening will be used for screening and to determine eligibility.
  • Willingness to be randomly assigned to medication class (SGLT2i or GLP-1 RA or both) and fill prescription through personal pharmacy benefit while having other medications adjusted for safety
  • Willingness to avoid starting a therapy in the alternative treatment group (e.g., if randomized to GLP-1 RA, avoid starting an SGLT2i) unless strongly recommended by the participant's usual care provider.
  • If taking one of the study medication classes, willingness to stop SGLT2i or GLP-1 RA and be randomly assigned to one of the two medication classes
  • Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities

Exclusion criteria

Exclusion Criteria:

  • Known or suspected diabetes of other cause (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.)
  • Any background diabetes medication regimen will be allowed in this pragmatic trial with the following proviso:

    o Participants taking basal-bolus, prandial, or multiple daily injection insulin (MDI) regimens (e.g., short-acting in combination with long-acting insulin, called MDI regimens) are eligible only if the research staff attests that there has been communication with the usual diabetes care provider and that the provider has agreed to manage insulin adjustment with initiation of study medications. If such agreement has not been obtained, participants taking MDI regimens are excluded.

  • History of diabetic ketoacidosis
  • Active diabetic foot ulcer
  • History of pancreatitis
  • Heart failure as a primary reason for hospitalization within the past year
  • Known \<40%
  • Known urinary albumin-to-creatinine ratio >200 mg/g at screening
  • Estimated (eGFR) less than 45 ml/min/1.73m2 measured within 12 months prior to screening. The most recent value available at screening will be used for screening and to determine eligibility.
  • Known inability to afford study medication through current insurance coverage.
  • If a woman of , the patient or partner is unwilling to use
  • Active treatment for cancer, planned treatment for cancer, or recent active cancer with likelihood of recurrence or progression, which, in the opinion of the site investigator, has a likelihood of recurrence that would interfere with study therapy prior to 2028

    • Treated cancer with no evidence of disease, no evidence of disease progression, and no planned change in therapy is allowed. Examples of allowable cancers include:
    • Breast cancer stable after active treatment, managed with long-term anti-estrogen therapy
    • Prostate cancer being observed
    • Stage 0 or 1 tumors status post resection or other definitive treatment
    • Other similarly stable cancer comorbidities
  • History of solid organ or bone marrow transplant
  • Allergy to SGLT2 inhibitor or GLP-1 receptor agonist
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6,000 participants (estimated)

Study arms

  • Active comparator
    Sodium-glucose cotransporter-2 inhibitor (SGLT2i)

    Therapy with an SGLT2i with proven cardiovascular benefit. This means either canagliflozin, dapagliflozin, or empagliflozin

    Drug: SGLT2 inhibitor

  • Active comparator
    Glucagon-like peptide-1 receptor agonist (GLP-1 RA)

    Therapy with a GLP-1 RA with proven cardiovascular benefit. This means either dulaglutide, liraglutide, or semaglutide.

    Drug: GLP-1 receptor agonist

Interventions

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Total (first and recurrent) cardiovascular, kidney, and death events

    total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality

    Time frame: Through study completion, with an average follow up of approximately 3 years

07

Study locations

36 of 36 sites recruiting
  • Longwood Research LLC
    Huntsville, Alabama 35801, United States
    Recruiting
  • HonorHealth Research & Innovation Institute
    Scottsdale, Arizona 85258, United States
    Recruiting
  • Eastside Clinical Research Associates
    Los Angeles, California 90022, United States
    Recruiting
  • Kendall South Medical Center, Inc
    Miami, Florida 33185, United States
    Recruiting
    • Denise Moreno · Contactfrontdesk@floridatrials.org · 305-388-1118
    • Rafael Chiong, MD · Principal investigator
    • Enrique Vazquez Escarpanter, MD · Sub investigator
  • South Florida Research Solutions, LLC
    Pembroke Pines, Florida 33028, United States
    Recruiting
    • Smelda Ferrin · Contactsferrin@sfresearch.net · 954-986-3067
    • Dennis Spiller, DO · Principal investigator
    • Julio Tallet, MD · Sub investigator
  • NSC Research, Inc.
    Johns Creek, Georgia 30024, United States
    Recruiting
    • Charlotte Mall · Contactinfo@nscresearch.org · 678-507-0838
    • Narendra Singh, MD · Principal investigator
    • Taylor Mabe, NP-C · Sub investigator
    • Dhaval Shah, MD · Sub investigator
  • Herman Clinical Research
    Suwanee, Georgia 30024, United States
    Recruiting
    • Morgan Echols · Contactmechols.hcr@gmail.com · 678-739-2765
    • Lee Herman, MD · Principal investigator
    • Amit Narayan, MD · Sub investigator
  • University of Illinois Chicago
    Chicago, Illinois 60612, United States
    Recruiting
    • Julia Law · Contactjulielaw@uic.edu · 773-505-0169
    • Brian Layden, MD · Principal investigator
    • Yuval Eisenberg, MD · Sub investigator
  • Rush University Medical Center
    Hinsdale, Illinois 60521, United States
    Recruiting
    • Sharon Glinski · Contactsharon_glinski@rush.edu · 630-724-1792
    • Ankitaben Han, MD, MS · Principal investigator
    • Sameer Panjwani, MD · Sub investigator
    • Jill K Marcus, MD · Sub investigator
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
    • Laura Seegmiller · Contactlaura-seegmiller@uiowa.edu · (319) 331-8773
    • Jeffrey D Quinlan, MD · Principal investigator
    • Hussain Banu, MBBS · Sub investigator
    • Korey Kennelty, PharmD, MS, PhD, BCGP · Sub investigator
  • University of Kansas Medical Center
    Fairway, Kansas 66205, United States
    Recruiting
    • Erica Lower, CCRP · Contactelower@kumc.edu · 913-588-6052
    • Kristin K Grdinovac, MD · Principal investigator
    • Ethan Alexander, MD · Sub investigator
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21205, United States
    Recruiting
    • Jamie Hyman · ContactPRECIDENTD@jhmi.edu · 443-927-8723
    • Maya Venkataramani, MD · Principal investigator
    • Dan Ford, MD · Sub investigator
  • MedStar Union Memorial Hospital
    Baltimore, Maryland 21218, United States
    Recruiting
    • Flossine Brown, BS, CRC · Contactflossine.brown@medstar.net · 410-554-4451
    • Adline Ghazi, MD · Principal investigator
    • Sadaf Mustafa, MD · Sub investigator
  • MedStar Health Research Institute - Good Samaritan Hospital
    Baltimore, Maryland 21239, United States
    Recruiting
    • Sariat Ibrahim · ContactSariat.Ibrahim@medstar.net · 443-444-2263
    • Jean Park, MD · Principal investigator
    • Adline Ghazi, MD · Sub investigator
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • UMass Chan Medical School
    Worcester, Massachusetts 01655, United States
    Recruiting
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Brittany Williams · Contactbriplunk@med.umich.edu · 734-998-2497
    • David Broome, MD · Principal investigator
  • Essentia Health
    Duluth, Minnesota 55805, United States
    Recruiting
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Sarah Manser · ContactPRECIDENTD@umn.edu · 612-301-3105
    • Elizabeth Rogers, MD, MAS · Principal investigator
    • Anne Bantle, MD, MS · Sub investigator
  • University of Missouri-Columbia
    Columbia, Missouri 65212, United States
    Recruiting
    • Katelyn Smith · ContactMUPRECIDENTD@health.missouri.edu · 833-970-0046
    • Camilla Manrique Acevedo, MD · Principal investigator
    • Katherine Pierce, PhD · Sub investigator
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    Recruiting
    • Khadieja M Abuzaho · Contactkabuzaho@unmc.edu · 402-559-4815
    • Cyrus Desouza, MBBS · Principal investigator
    • Amber Brown Keebler, MD · Sub investigator
    • Shubham Agarwal, MBBS · Sub investigator
  • Naomi Berrie Diabetes Center at New York Presbyterian-Columbia University
    New York, New York 10032, United States
    Recruiting
    • Angel Suzana · Contactprecidentd@cumc.columbia.edu · 212-851-5492
    • Jacqueline Lonier, MD · Principal investigator
    • Nina Suda, MD · Sub investigator
  • Atrium Health Family Medicine Research Department
    Charlotte, North Carolina 28207, United States
    Recruiting
    • Andrea Price · Contactprecidentd@advocatehealth.org · 704-304-7176
    • Hazel Tapp, PhD · Principal investigator
    • Emily Manlove Manlove, MD · Sub investigator
    • May Royer, MD · Sub investigator
    • Lindsay Shade, PA-C · Sub investigator
  • Duke University Hospital
    Durham, North Carolina 27710, United States
    Recruiting
    • Chad Harrell · ContactDukePRECIDENTD@duke.edu · 919-668-9049
    • W. Schuyler Jones, MD · Principal investigator
    • Ranee Chatterjee, MD · Sub investigator
  • Wooster Heart Group
    Wooster, Ohio 44691, United States
    Recruiting
    • John Roof · Contactjroof@bloomingtonmedical.org · 330-202-5700
    • Cyril S Ofori, MD · Principal investigator
    • Toni King, MD · Sub investigator
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
    • Aly Carlson · Contactprecidentd@ohsu.edu · 971-610-3005
    • Rodica Busui, MD, PhD · Principal investigator
  • Geisinger Medical Center
    Danville, Pennsylvania 17821, United States
    Recruiting
    • Megan Oliveri · Contactmeoliveri@geisinger.edu · 1-866-219-5148, Option 2
    • Alexander Chang, MD, MS, FAHA, FASN · Principal investigator
    • Anthony Olson, PharmD, PhD, FAPhA · Sub investigator
    • Eric Wright, PharmD, MPH · Sub investigator
    • Waleed Zafar, MD · Sub investigator
  • Temple University Lewis Katz School of Medicine
    Philadelphia, Pennsylvania 19140, United States
    Recruiting
    • Jackson Weiler · Contactjackson.weiler@temple.edu · 267-225-4836
    • Daniel J Rubin, MD · Principal investigator
    • Ajaykumar D Rao, MD · Sub investigator
  • Family Care Center at Kent Hospital
    Pawtucket, Rhode Island 02860, United States
    Recruiting
    • Angela Larkin · ContactALarkin@kentri.org · 401-921-9066
    • Caroline Richardson, MD · Principal investigator
    • Charles Eaton, MD · Sub investigator
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Audra Wiser · Contactwisera@musc.edu · (843) 876-9928
    • Harsha Karanchi, MD · Principal investigator
    • Mary Leigh Goodman, DNP, APRN, FNP-C · Sub investigator
  • South Carolina Clinical Research, LLC
    Orangeburg, South Carolina 29118, United States
    Recruiting
    • Payton Padgett · Contactppadgett@scnephrology.net · 803-531-2220
    • Moustafa A Moustafa, MD · Principal investigator
    • Radames Zuquello, MD · Sub investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Alesia Pruitt · Contactalesia.l.pruitt@vumc.org · 615-421-3082
    • Leslee Matheny, MD · Principal investigator
    • Russell Rothman, MD · Sub investigator
  • Premier Internal Medicine Associates of Houston
    Katy, Texas 77493, United States
    Recruiting
    • Nausheen Mujeeb · ContactIMresearch5@medacro.com · 281-398-8044
    • Nadia Abbasi, MD · Principal investigator
    • Christina Bolin · Sub investigator
  • North Dallas Research Associates
    McKinney, Texas 75069, United States
    Recruiting
    • Samina Ahsanullah · Contactsamina@ndresearch.com · 972-529-6939
    • Muhammad Akram Khan, MD · Principal investigator
    • Ambreen Ashfaque, MD · Sub investigator
  • Kidney and Hypertension Specialists, PLLC
    Manassas, Virginia 20110, United States
    Recruiting
    • Hanan Ebjad, MD, MHSA · ContactResearch@NovaKidney.Com · 703-361-7341
    • Rashida Rahman, MD · Principal investigator
    • Hanan Ebjad Ebjad, MD, MHSA · Sub investigator
    • Priya Chaddah, PA-C · Sub investigator
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Kailie Roth · Contactkroth@mcw.edu · 414-805-8104
    • Jake Decker, MD · Principal investigator
    • Jeffrey Whittle, MD · Sub investigator
08

References and documents

Publications

  • Wexler DJ, Mayberry LS, Nelson LA, Lema-Driscoll J, Flores LC, Malloy M, MacFadyen JG, Shen J, Zaharris E, Karanchi H, Chatterjee R, Benziger CP, Decker JE, Kalyani R, Manrique-Acevedo C, Lonier J, Simeone E, Mieras K, Siqueira ARO, Rothman RL, Jones WS, Glynn RJ, Everett BM. Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial. Am Heart J. 2026 Apr;294:107332. doi: 10.1016/j.ahj.2025.107332. Epub 2025 Dec 26. PubMed 41456635 ↗

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Mar 2029, 77 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 77 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 25, 2022
StartActual
Sep 26, 2022
Primary completionEst.
Mar 1, 2029
CompletionEst.
Mar 1, 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05390892
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Brendan M. Everett (Associate Physician and Associate Professor, Brigham and Women's Hospital) — Principal investigator
First posted
May 25, 2022
Start date
Sep 26, 2022
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Brendan Everett, MD, MPH
Contact
PRECIDENTDccc@bwh.harvard.edu
617-732-8790
Maureen Malloy
Contact
PRECIDENTDccc@bwh.harvard.edu
617-732-8773

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SGLT2 inhibitors · GLP-1 Mimetic · Semaglutide

Start the discussion